.
MergerLinks Header Logo

New Deal


Announced

ConvaTec Group to acquire Triad Life Sciences for $450m.

Financials

Edit Data
Transaction Value£335m
Consideration TypeContingent Deferred Consideration, Cash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Acquisition

Single Bidder

Private

Pending

medical devices

United States

Majority

Cross Border

wound biologics

Medical Equipment

Friendly

Synopsis

Edit

ConvaTec Group, a global medical solutions company focused on the management of chronic conditions, agreed to acquire Triad Life Sciences, a US-focused medical device company that develops biologically-derived innovative products to address unmet clinical needs in surgical wounds, chronic wounds and burns, for $450m. "Today’s announcement marks another successful step in our strategic intent of pivoting to sustainable and profitable growth. This transaction will strengthen our Wound Care business and enable ConvaTec to enter the rapidly growing wound biologics segment. Triad Life Sciences has innovative and differentiated products and an exciting pipeline which is consistent with our vision – Pioneering trusted medical solutions to improve the lives we touch. We are delighted that Russ and the team have decided to join ConvaTec," Karim Bitar, ConvaTec Group CEO.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US